Program
E-3810
Also written as “E3810”, “Lucitanib” and “AL3810”.
Its studies are mostly in Thymoma · Genital Neoplasms, Female · Breast Neoplasms · Small Cell Lung Carcinoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eisai | 40 open or running | phase 3since Sep 12, 2005 | Sep 12, 2005 | none ahead |
| Haihe Biopharma | 40 open or running | phase 3since Jan 16, 2020 | Dec 16, 2016 | none ahead |
| Clovis Oncology | 30 open or running | phase 2since Apr 7, 2014 | Apr 7, 2014 | none ahead |
Also a collaborator on its studies: Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2005First study: phase 3 study in Non-erosive Gastroesophageal Reflux DiseaseNew to EisaiEisai · NCT00165646 · 288 enrolled · Japan
- Oct 9, 2008Phase 3 study in Esophagitis, PepticEisai · NCT00770913 · 337 enrolled · Japan
- Jun 28, 2010Phase 1 study in HealthyEisai · NCT01153659 · 90 enrolled · United States
- Jul 18, 2011Phase 3 study in Stomach UlcerEisai · NCT01397448 · 472 enrolled · Japan
- Apr 7, 2014Clovis Oncology's first study: phase 2 study in Carcinoma, Non-Small-Cell LungNew to Clovis OncologyClovis Oncology · NCT02109016 · 18 enrolled · United States, France, Germany and more
- Jul 25, 2014Phase 2 study in Breast NeoplasmsClovis Oncology · NCT02202746 · 178 enrolled · United States
- Dec 16, 2016Haihe Biopharma's first study: phase 1 study in Advanced Solid TumorsNew to Haihe BiopharmaHaihe Biopharma · NCT03117101 · 17 enrolled · China
- Jul 20, 2017Phase 1 study in Colorectal NeoplasmsHaihe Biopharma · NCT03260179 · 60 enrolled · China
- Jul 19, 2019Phase 2 study in Genital Neoplasms, FemaleClovis Oncology · NCT04042116 · 227 enrolled · United States, Austria, Belgium and more
- Jan 16, 2020Phase 3 study in Small Cell Lung CarcinomaHaihe Biopharma · NCT04254471 · 313 enrolled · China
- Sep 11, 2026Phase 2 study in ThymomaHaihe Biopharma · NCT07824505 · 74 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07824505Thymoma · China | 2 | Completed | Haihe Biopharma | Sep 6, 2021 | 74 |
| NCT04254471Small Cell Lung Carcinoma · China | 3 | UNKNOWN | Haihe Biopharma | May 22, 2022 | 313 |
| NCT04042116Genital Neoplasms, Female · United States, Austria, Belgium and more | 2 | Suspended | Clovis Oncology | Jul 2023 | 227 |
| NCT03260179Colorectal Neoplasms · China | 1 | UNKNOWN | Haihe Biopharma | Jan 31, 2019 | 60 |
| NCT03117101Advanced Solid Tumors · China | 1 | Completed | Haihe Biopharma | Sep 2016 | 17 |
| NCT02202746Breast Neoplasms · United States | 2 | Terminated | Clovis Oncology | Jan 17, 2017 | 178 |
| NCT02109016Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Terminated | Clovis Oncology | Apr 1, 2016 | 18 |
| NCT01397448Stomach Ulcer · Japan | 3 | Completed | Eisai | Mar 2013 | 472 |
| NCT01153659Healthy · United States | 1 | Completed | Eisai | Aug 2010 | 90 |
| NCT00770913Esophagitis, Peptic · Japan | 3 | Completed | Eisai | Nov 2009 | 337 |
| NCT00165646Non-erosive Gastroesophageal Reflux Disease · Japan | 3 | Completed | Eisai | Oct 2005 | 288 |
How it is read
Names in the registry
- “E3810”, 8 entries
- “Lucitanib”, 6 entries
- “AL3810”, 4 entries
- “lucitanib 15 mg QD”, 1 entry
- “lucitanib 10 mg QD”, 1 entry
Conditions, from the studies’ own filings
- Thymoma, 1 study
- Genital Neoplasms, Female, 1 study
- Breast Neoplasms, 1 study
- Small Cell Lung Carcinoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.